Sugi Predict

Sugi Predict / Compounds / SCHEMBL1703729

SCHEMBL1703729

SCHEMBL1703729

CN(C)C(=O)Cn1cc(N)cn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCNC P24863 9/20 0.45
▸ CDK8 P49336 9/20 0.45
▸ FLT3 P36888 1/20 0.45
▸ MYLK Q15746 1/20 0.45
▸ AURKB Q96GD4 1/20 0.45
▸ CILK1 Q9UPZ9 1/20 0.45
▸ CDK11A Q9UQ88 1/20 0.45
▸ PDK2 Q15119 1/20 0.42
▸ ALOX5AP P20292 5/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ MET P08581 1/20 0.39
▸ ALK Q9UM73 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ TYK2 P29597 1/20 0.38
▸ JAK3 P52333 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27174663 0.84 ERCC5 (0.47) CCNCCDK8FLT3MYLKAURKB
SCHEMBL671192 0.83 PDK2 (0.45) CCNCCDK8FLT3MYLKAURKB
SCHEMBL15895023 0.81 L3MBTL1 (0.40) PDK2JAK2LMNAMAPT
SCHEMBL10044956 0.81 ALPI (0.50) CCNCCDK8FLT3MYLKAURKB
SCHEMBL17605207 0.79 CCNC (0.47) CCNCCDK8FLT3MYLKAURKB
SCHEMBL12492720 0.79 CCNC (0.45) CCNCCDK8FLT3MYLKAURKB
SCHEMBL1703493 0.78 MAPT (0.42) PDK2ALOX5APLMNAMAPT
SCHEMBL673074 0.78 MAPT (0.42) PDK2ALOX5APLMNAMAPT
SCHEMBL12020134 0.78 CCNC (0.44) CCNCCDK8FLT3MYLKAURKB
SCHEMBL16472361 0.78 CCNC (0.46) CCNCCDK8FLT3MYLKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114292274-B Pyrrolo [2,3-d ] pyrimidine derivatives as JAK kinase inhibitors, and preparation method and application thereof 中国药科大学 2023-12-19 — — CN disclosed
CN-114292274-A Pyrrolo [2,3-d ] pyrimidine derivatives as JAK kinase inhibitors, and preparation method and application thereof 中国药科大学 2022-04-08 — — CN disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
EP-3129378-B1 BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER KAINOS MEDICINE INC (KR) 2019-06-26 — — EP disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-9187453-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-17 — — US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
US-20150005281-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2015-01-01 — — US disclosed
CN-104169272-A Pyrimidine-2,4-diamine derivatives as kinase inhibitors CELLZOME LTD 2014-11-26 — — CN disclosed
EP-2794598-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS Cellzome Limited (GB) 2014-10-29 — — EP disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 — — WO disclosed
WO-2013092854-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2013-06-27 — — WO disclosed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 — — US disclosed
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 — — EP disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US disclosed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB CCNC 341/4885CDK8 98/4885FLT3 20/4885
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK CCNC 2943/4885CDK8 1781/4885FLT3 504/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK CCNC 2580/4885CDK8 1102/4885FLT3 310/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK CCNC 2943/4885CDK8 1781/4885FLT3 504/4885
US-20150005281-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS JAK2, JAK1, JAK3 CCNC 502/4885CDK8 75/4885FLT3 53/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK CCNC 2984/4885CDK8 1662/4885FLT3 407/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK CCNC 2984/4885CDK8 1662/4885FLT3 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.